ArticleFrontiers in microbiology2026
TRACE: reconstructing fragmented microbial landscapes for high-resolution antimicrobial resistance surveillance.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Comprehensive mapping of Antimicrobial Resistance (AMR) dynamics is a cornerstone of systems microbiology and global health security. However, the precise characterization of microbial interactions within clinical ecosystems is severely confined by the fragmentation of phenotypic evidence. Critical data points, including pathogen identity, anatomical niche, and susceptibility profiles, are often buried within unstructured clinical narratives. This fragmentation creates a blind spot in surveillance, where the ecological signals of rare but critical resistance phenotypes are lost, preventing a systems-level understanding of microbial evolution. Methods: To bridge this gap, we propose the Triple-based Reconstruction for Antimicrobial Clinical Evidence (TRACE) framework, a systems-computational approach that treats clinical records as unstructured microbiological sensors. Unlike traditional classification models, our approach focuses on the biological reconstruction of evidence. It first aggregates scattered findings into coherent Organism-Specimen-Susceptibility biological clusters. To resolve the scarcity of data for underrepresented pathogens, which represent the long-tail of biodiversity, we employ a constraint-based Results: Validated on the MIMIC-III and MIMIC-IV datasets, TRACE demonstrates a superior ability to recover lost microbial signals. On the challenging MIMIC-IV benchmark, it achieves a Macro-F1 score of 15.4% and a Precision@5 of 70.3%. More importantly, the system successfully disentangles clinically similar but biologically distinct resistance phenotypes, significantly reducing the misidentification of rare pathogen-drug combinations. Conclusion: By resolving evidence fragmentation and effectively expanding the feature space for underrepresented microorganisms, TRACE provides a robust solution for fine-grained infectious disease characterization. This framework establishes a foundation for high-precision AMR phenotype identification, paving the way for more reliable monitoring of resistance trends in clinical ecosystems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.